Maravai LifeSciences (MRVI) vs Stoke Therapeutics (STOK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Maravai LifeSciences (MRVI) has outperformed Stoke Therapeutics (STOK) over the past year, gaining 86.1% versus a loss of 8.6%. Over five years, STOK leads with a +6.8% price change compared with -83.2% for MRVI. Maravai LifeSciences is the larger company by market cap ($1.81 billion vs $1.75 billion), about 1.0 times the size, while Stoke Therapeutics is growing revenue faster (+404.5% vs -28.3%).
Stoke Therapeutics converts more of its revenue into profit, with a net margin of -3.7% versus -70.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MRVI | STOK |
|---|---|---|
| Share price | $6.98 | $26.81 |
| Market cap | $1.81B | $1.75B |
| 1-day change | -2.92% | -0.45% |
| YTD return | +114.77% | -15.53% |
| 1-year return | +86.13% | -8.62% |
| 5-year return | -83.18% | +6.77% |
| EPS (TTM) | $-0.44 | $-3.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $185.74M | $184.42M |
| Revenue growth (YoY) | -28.34% | +404.50% |
| Net income (latest FY) | $-130.77M | $-6.88M |
| Gross margin | 18.30% | — |
| Operating margin | -115.89% | -11.16% |
| Net margin | -70.41% | -3.73% |
| 52-week high | $9.42 | $40.22 |
| 52-week low | $2.80 | $22.05 |
| Distance from 52-week high | -25.90% | -33.34% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +38.11% | +73.00% |
| Average volume | 2.72M | 1.02M |
| Shares outstanding | 149.25M | 65.41M |
| Employees | 410 | 170 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MRVI has outperformed STOK by 94.8 percentage points over the past year.
- Stoke Therapeutics is more profitable, keeping -3.7 cents of every revenue dollar as net income versus -70.4 cents for Maravai LifeSciences.
- Stoke Therapeutics grew revenue faster in its latest fiscal year (+404.50% vs -28.34%).
About Maravai LifeSciences
MRVI stock →Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS.
Health Care · Biotechnology: Pharmaceutical Preparations · 410 employees
About Stoke Therapeutics
STOK stock →Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression.
Health Care · Biotechnology: Pharmaceutical Preparations · 170 employees
MRVI vs STOK FAQ
Which is bigger, Maravai LifeSciences or Stoke Therapeutics?
Maravai LifeSciences (MRVI) is larger, with a market capitalization of $1.81B compared with $1.75B for Stoke Therapeutics (STOK).
Which stock has performed better over the past year, MRVI or STOK?
MRVI returned +86.13% over the past 12 months, compared with -8.62% for STOK (price return, excluding dividends). Past performance does not predict future results.
Are Maravai LifeSciences and Stoke Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.